Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €28.78 EUR
Change Today -0.22 / -0.76%
Volume 150.0
AB3A On Other Exchanges
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Edward M. Kaye M.D., Ph.D.

Interim Chief Executive Officer, Chief Medical Officer and Senior Vice President, Sarepta Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 7 board members in 1 different organizations across 2 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Edward M. Kaye, also known as Ed, M.D. Ph.D., has been Chief Executive Officer of Sarepta Therapeutics, Inc since March 31, 2015. Dr. Kaye has been the Chief Medical Officer and Senior Vice President of Sarepta Therapeutics, Inc since June 20, 2011. Dr. Kaye serves as a Neurological Consultant at Children's Hospital of Boston. He has specific experience with pediatric neuromuscular conditions. Dr. Kaye joined AVI from Genzyme, where he served as Group Vice President ...

Read Full Background

Corporate Headquarters*

215 First Street
Cambridge, Massachusetts 02142

United States

Phone: 617-274-4000
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.


Unknown/Other Education
Boston University
Loyola University of Chicago
Stritch School Of Medicine, Loyola University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$399,017

Stock Options*

All Other Compensation$17,997
Exercisable Options194,485
Exercisable Options Value$1,038,252
Unexercisable Options137,533
Unexercisable Options Value$288,430
Total Value of Options$1,326,682
Total Number of Options371,956

Total Compensation*

Total Annual Cash Compensation$548,690
Total Short Term Compensation$399,017
Other Long Term Compensation$17,997
Total Calculated Compensation$1,703,921
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €28.78 EUR -0.22


Ali Mortazavi Chief Executive (leave of absence) and Director
Silence Therapeutics plc
200.0K GBP
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at